JP2005531557A5 - - Google Patents

Download PDF

Info

Publication number
JP2005531557A5
JP2005531557A5 JP2004505050A JP2004505050A JP2005531557A5 JP 2005531557 A5 JP2005531557 A5 JP 2005531557A5 JP 2004505050 A JP2004505050 A JP 2004505050A JP 2004505050 A JP2004505050 A JP 2004505050A JP 2005531557 A5 JP2005531557 A5 JP 2005531557A5
Authority
JP
Japan
Prior art keywords
effective
compound
use according
opiate receptor
appetite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004505050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005531557A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/004428 external-priority patent/WO2003097051A2/en
Publication of JP2005531557A publication Critical patent/JP2005531557A/ja
Publication of JP2005531557A5 publication Critical patent/JP2005531557A5/ja
Pending legal-status Critical Current

Links

JP2004505050A 2002-05-17 2003-04-28 選択的オピエート受容体モジュレーターとして効果的な化合物の使用 Pending JP2005531557A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02011047 2002-05-17
PCT/EP2003/004428 WO2003097051A2 (en) 2002-05-17 2003-04-28 Use of compounds that are effective as selective opiate receptor modulators

Publications (2)

Publication Number Publication Date
JP2005531557A JP2005531557A (ja) 2005-10-20
JP2005531557A5 true JP2005531557A5 (cg-RX-API-DMAC7.html) 2007-05-17

Family

ID=29433078

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004505050A Pending JP2005531557A (ja) 2002-05-17 2003-04-28 選択的オピエート受容体モジュレーターとして効果的な化合物の使用

Country Status (20)

Country Link
US (1) US20050176746A1 (cg-RX-API-DMAC7.html)
EP (2) EP2074997A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005531557A (cg-RX-API-DMAC7.html)
KR (1) KR101108014B1 (cg-RX-API-DMAC7.html)
CN (2) CN100411618C (cg-RX-API-DMAC7.html)
AR (1) AR040028A1 (cg-RX-API-DMAC7.html)
AT (1) ATE429226T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003242527B2 (cg-RX-API-DMAC7.html)
BR (1) BR0309969A (cg-RX-API-DMAC7.html)
CA (1) CA2486000A1 (cg-RX-API-DMAC7.html)
DE (1) DE60327315D1 (cg-RX-API-DMAC7.html)
DK (1) DK1505974T3 (cg-RX-API-DMAC7.html)
ES (1) ES2325782T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA04011333A (cg-RX-API-DMAC7.html)
PE (1) PE20040455A1 (cg-RX-API-DMAC7.html)
PL (1) PL371596A1 (cg-RX-API-DMAC7.html)
RU (1) RU2336871C2 (cg-RX-API-DMAC7.html)
TW (1) TWI314053B (cg-RX-API-DMAC7.html)
WO (1) WO2003097051A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200410160B (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
BR122018074353B8 (pt) 2003-01-28 2023-05-02 Ironwood Pharmaceuticals Inc composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1870096A3 (en) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
JP2007509865A (ja) * 2003-10-30 2007-04-19 ティオガ ファーマシュウティカルズ,インコーポレイテッド 神経障害の治療における選択的オピエート受容体調節物質の使用
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
CN101677997B (zh) * 2007-03-30 2012-05-09 泰奥加制药公司 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
JP5964589B2 (ja) 2008-12-03 2016-08-03 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼcアゴニストの製剤およびその使用方法
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN103819403B (zh) 2008-12-31 2017-01-04 阿德利克斯公司 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法
RU2413512C1 (ru) * 2009-07-29 2011-03-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" Средство, обладающее каппа-опиоидной агонистической активностью
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
WO2012012410A2 (en) * 2010-07-19 2012-01-26 Dr. Reddy's Laboratories Ltd. Kappa opioid receptor agonists
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
RU2015107019A (ru) 2012-08-21 2016-10-10 Эрделикс Инк. Соединения и способы для ингибирования nhe-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой и заболеваний желудочно-кишечного тракта
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CN105392483B (zh) 2013-04-12 2019-03-15 阿德利克斯公司 用于抑制磷酸盐转运的nhe3结合化合物和方法
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
EA023231B1 (ru) * 2013-07-18 2016-05-31 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт нормальной физиологии имени П.К. Анохина" Российской академии медицинских наук (ФГБУ "НИИНФ им. П.К. Анохина" РАМН) Применение агониста каппа опиоидных рецепторов периферического действия ici 204,448 для приготовления средств для лечения синдрома отмены никотина
WO2015065867A2 (en) * 2013-10-28 2015-05-07 Cara Therapeutics, Inc. Peripheral kappa opioid receptor agonists for preventing, inhibiting or treating nausea and vomiting
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
KR20240090875A (ko) 2017-01-09 2024-06-21 알데릭스, 인코포레이티드 위장관 장애를 치료하는 데 유용한 화합물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889860A (en) * 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
DE4034785A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
DE3935371A1 (de) 1988-12-23 1990-07-05 Merck Patent Gmbh Stickstoffhaltige ringverbindungen
US5389686A (en) * 1989-02-20 1995-02-14 Jouveinal Sa Analgesic properties of fedotozine
DE4215213A1 (de) 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4215231C1 (en) 1992-05-09 1993-05-13 Dornier Luftfahrt Gmbh, 8031 Wessling, De Arrangement for mfg. fibre reinforced thermoplastic components - including unit for accommodating component, pressurising unit for assembled component and heating unit
DE19523502A1 (de) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) * 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
DE69833000T2 (de) * 1997-09-26 2006-09-07 Noven Pharmaceuticals, Inc., Miami Bio-klebemittelzusammensetzungen
US20010051181A1 (en) * 1997-12-22 2001-12-13 Van Osdol William W. Novel formulations for the transdermal administration of asimadoline
JPH11343244A (ja) * 1998-03-30 1999-12-14 Taisho Pharmaceut Co Ltd 経口用組成物
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
PL209952B1 (pl) * 1998-07-14 2011-11-30 Janssen Pharmaceutica Nv Wyizolowana cząsteczka kwasu nukleinowego, wyizolowany ludzki neurotroficzny czynnik wzrostu, plazmid, wektor ekspresyjny, komórka gospodarza, zastosowania cząsteczki kwasu nukleinowego, zastosowania neurotroficznego czynnika wzrostu, kompozycje faramaceutyczne, przeciwciało oraz sposób wykrywania neurotroficznego czynnika wzrostu
DE60018225T2 (de) * 1999-03-01 2005-12-29 Pfizer Products Inc., Groton Oxamsäuren mit einer Cyanogruppe als Liganden für den Thyroidrezeptor
EP1359912A4 (en) * 2000-06-19 2006-05-03 Eisai Co Ltd NEW METHODS USING PYRIDINE DERIVATIVES
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
DE10030893A1 (de) * 2000-06-23 2002-01-03 Henkel Kgaa Paraaminophenol-Derivate und deren Verwendung
US6262062B1 (en) * 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
AU2002364517A1 (en) * 2001-11-30 2003-06-17 Sepracor Inc. Tramadol analogs and uses thereof

Similar Documents

Publication Publication Date Title
RU2004137091A (ru) Применение соединений, которые являются эффективными как селективные модуляторы опиатного рецептора
PT2701693T (pt) Tapentadol para prevenção e tratamento de depressão e ansiedade
CN1468111A (zh) 治疗急性、慢性疼痛和/或神经病性疼痛和偏头痛的药物组合物
WO2011008298A2 (en) Novel axomadol dosage forms
PL204075B1 (pl) Zastosowanie kompozycji farmaceutycznej zawierającej metoklopramid oraz tramadol do wytwarzania leku
JPWO2002053153A1 (ja) 神経因性疼痛治療及び予防薬
JP2009242366A (ja) 持続性解熱鎮痛消炎剤
WO2004096202A1 (en) Pharmaceutical formulation comprising anti-obesity agent and acidulant
CN105848655B (zh) 用于注意力和认知障碍的、以及用于与神经变性障碍相关联的痴呆的新疗法
JP6116676B2 (ja) (1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミンおよびパラセタモールまたはプロパセタモールを含む医薬組成物
US20090048233A1 (en) Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination
JP2008519055A (ja) ミルタザピンと興奮剤複合物の併用投与の相乗効果
JP7270901B2 (ja) 男性の避妊のための非ホルモン性組成物および方法
JP7656339B2 (ja) 疼痛を緩和するためのイブプロフェン及びトラマドールの組合せ
TWI424850B (zh) 包含非類固醇類抗發炎藥物及秋水仙鹼甙(colchicoside)衍生物之活性成分之新組合
KR20010099648A (ko) 신규 조성물
JP2008106028A (ja) 慢性疼痛の治療におけるフリバンセリンの使用
WO2001034140A1 (en) Pharmaceutical formulation
JP2826843B2 (ja) 消化管運動賦活剤
WO2004058237A1 (en) Therapeutic use of sibutramine and analogues thereof
JP2008007502A (ja) 肥満治療剤並びに肥満の治療及び予防方法
KR20220110259A (ko) 통증 질환에 사용하기 위한 미르타자핀 및 티자니딘 배합물
HK40067137B (en) Combination of ibuprofen and tramadol for relieving pain
HK40067137A (en) Combination of ibuprofen and tramadol for relieving pain
WO2020091711A1 (en) Pharmaceutical combinations for the treatment of pain